Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas
Glioblastoma (GBM) is the most prevalent malignant brain tumor. Current standard-of-care treatments offer limited benefits for patient survival. Virotherapy is emerging as a novel strategy to use oncolytic viruses (OVs) for the treatment of GBM. These engineered and non-engineered viruses infect and...
Saved in:
| Main Authors: | Natalie M. Meléndez-Vázquez, Candelaria Gomez-Manzano, Filipa Godoy-Vitorino |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/16/11/1775 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas
by: Natalie M. Meléndez-Vázquez, et al.
Published: (2024-03-01) -
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma
by: Emily M. Ringwalt, et al.
Published: (2024-12-01) -
Optimizing Oncolytic Virotherapy for Malignant Glioma: From Bench to Bedside
by: Jiang W, et al.
Published: (2025-08-01) -
ONCOLYTIC VIROTHERAPY IN GLIOBLASTOMA TREATMENT: PROGRESS AND CHALLENGES IN CLINICAL RESEARCH (LITERATURE REVIEW)
by: O. I. Kit, et al.
Published: (2020-12-01) -
Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas
by: Natalie M. Meléndez-Vázquez, et al.
Published: (2024-06-01)